Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Oct;76(4):1330–1337. doi: 10.1172/JCI112107

Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.

F A Siddiqui, E C Lian
PMCID: PMC424068  PMID: 3932464

Abstract

A novel platelet-agglutinating protein (PAP) was purified approximately 2,000-fold from the plasma of a patient with thrombotic thrombocytopenic purpura (TTP) by ammonium sulfate fractionation, DEAE-Sephacel and concanavalin A-Sepharose chromatographies. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with and without reduction, this preparation revealed a major protein band with a molecular weight of 37,000, and a minor band with a molecular weight of 32,000-34,000. After elution from the gel, only the 37,000-mol wt protein corresponding to the major band induced the platelet agglutination. When four normal plasmas and the recovery plasma from the same TTP patient were subjected to the similar purification steps, the 37,000-mol wt major band was absent. The 125I-PAP bound to the platelets in a concentration-dependent manner. The platelet agglutination induced by PAP was not inhibited by hirudin, heparin in the presence of antithrombin III, phenylmethylsulfonyl fluoride, apyrase, aspirin, or prostaglandin I2. However, it was inhibited by IgG from normal adults and from the same TTP patient after recovery. The anti-37,000-mol wt PAP antiserum prepared in the rabbit formed a single precipitin line against the highly purified PAP. Using this antiserum in the Western immunoblotting, the 37,000-mol wt protein band was found in the three TTP plasmas, of which the platelet-agglutinating activity was inhibited by the anti-37,000-mol wt PAP IgG. The 37,000-mol wt immunoprecipitin band was absent in the plasmas obtained from another two TTP patients, two normal subjects, two patients with idiopathic thrombocytopenic purpura, and two patients with disseminated intravascular coagulation. These results suggest that the 37,000-mol wt PAP is present only in certain cases of TTP, and is likely to be responsible for the formation of platelet thrombi in the microcirculation.

Full text

PDF
1330

Images in this article

1333Image
on p.1333
1335Image
on p.1335
1335Image
on p.1335
1335Image
on p.1335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ansell J. E., Slepchuk N. I., Jr, Pechet L. Platelet-aggregating factor in thrombotic thrombopenic purpura plasma. Blood. 1979 Oct;54(4):959–960. [PubMed] [Google Scholar]
  2. Bennett J. S., Hoxie J. A., Leitman S. F., Vilaire G., Cines D. B. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci U S A. 1983 May;80(9):2417–2421. doi: 10.1073/pnas.80.9.2417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Brandt J. T., Kennedy M. S., Senhausen D. A. Platelet aggregating factor in thrombocytopenic purpura. Lancet. 1979 Sep 1;2(8140):463–464. doi: 10.1016/s0140-6736(79)91510-1. [DOI] [PubMed] [Google Scholar]
  5. Bukowski R. M., King J. W., Hewlett J. S. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood. 1977 Sep;50(3):413–417. [PubMed] [Google Scholar]
  6. Burnette W. N. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981 Apr;112(2):195–203. doi: 10.1016/0003-2697(81)90281-5. [DOI] [PubMed] [Google Scholar]
  7. Burns E. R., Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood. 1982 Oct;60(4):1030–1037. [PubMed] [Google Scholar]
  8. Byrnes J. J., Lian E. C. Recent therapeutic advances in thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 1979 Winter;5(3):199–215. doi: 10.1055/s-0028-1087153. [DOI] [PubMed] [Google Scholar]
  9. Gorman R. R., Bunting S., Miller O. V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 1977 Mar;13(3):377–388. doi: 10.1016/0090-6980(77)90018-1. [DOI] [PubMed] [Google Scholar]
  10. Hamberg M., Svensson J., Samuelsson B. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci U S A. 1974 Oct;71(10):3824–3828. doi: 10.1073/pnas.71.10.3824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kinlough-Rathbone R. L., Packham M. A., Reimers H. J., Cazenave J. P., Mustard J. F. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187. J Lab Clin Med. 1977 Oct;90(4):707–719. [PubMed] [Google Scholar]
  12. Kwaan H. C. The pathogenesis of thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 1979 Winter;5(3):184–198. doi: 10.1055/s-0028-1087152. [DOI] [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Lian E. C., Harkness D. R., Byrnes J. J., Wallach H., Nunez R. Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood. 1979 Feb;53(2):333–338. [PubMed] [Google Scholar]
  15. Lian E. C., Mui P. T., Siddiqui F. A., Chiu A. Y., Chiu L. L. Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G. J Clin Invest. 1984 Feb;73(2):548–555. doi: 10.1172/JCI111242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lian E. C., Savaraj N. Effects of platelet inhibitors on the platelet aggregation induced by plasma from patients with thrombotic thrombocytopenic purpura. Blood. 1981 Aug;58(2):354–359. [PubMed] [Google Scholar]
  17. MARKWARDT F., WALSMANN P. Die Reaktion zwischen Hirudin und Thrombin. Hoppe Seylers Z Physiol Chem. 1958;312(1-3):85–98. [PubMed] [Google Scholar]
  18. McIntyre B. A., Philp R. B. Effect of three nonsteroidal anti-inflammatory agents on platelet function and prostaglandin synthesis in vitro. Thromb Res. 1978 Jan;12(1):67–77. doi: 10.1016/0049-3848(78)90086-5. [DOI] [PubMed] [Google Scholar]
  19. Myers T. J., Wakem C. J., Ball E. D., Tremont S. J. Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and antiplatelet agents. Ann Intern Med. 1980 Feb;92(2 Pt 1):149–155. doi: 10.7326/0003-4819-92-2-149. [DOI] [PubMed] [Google Scholar]
  20. Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed] [Google Scholar]
  21. Siddiqui F. A., Srivastava B. I. Terminal deoxyribonucleotidyl transferase from acute lymphoblastic leukemia cells and production of antisera. Biochim Biophys Acta. 1978 Jan 26;517(1):150–157. doi: 10.1016/0005-2787(78)90042-4. [DOI] [PubMed] [Google Scholar]
  22. Slatkin D. N., Stoner R. D., Adams W. H., Kycia J. H., Siegelman H. W. Atypical pulmonary thrombosis caused by a toxic cyanobacterial peptide. Science. 1983 Jun 24;220(4604):1383–1385. doi: 10.1126/science.6407109. [DOI] [PubMed] [Google Scholar]
  23. Walsh P. N., Mills D. C., White J. G. Metabolism and function of human platelets washed by albumin density gradient separation. Br J Haematol. 1977 Jun;36(2):287–296. doi: 10.1111/j.1365-2141.1977.tb00649.x. [DOI] [PubMed] [Google Scholar]
  24. Wautier J. L., Caen J. P. Pharmacology of platelet-suppressive agents. Semin Thromb Hemost. 1979 Spring;5(4):293–315. doi: 10.1055/s-0028-1087160. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES